CADTH reimbursement recommendation: Satralizumab (Enspryng) for the treatment of neuromyelitis optica spectrum disorder : recommendation : reimburse with conditions
Clinical evidence suggests that Enspryng should be reimbursed for NMOSD in patients who are 12 years and older, anti-AQP4 positive, have had at least 1 NMOSD relapse in the 12 months before initiation despite an adequate trial of other accessible preventive treatments for NMOSD, or the patient canno...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2021, April 2021
|
| Edition: | Version: 1.0 |
| Series: | CADTH reimbursement review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Clinical evidence suggests that Enspryng should be reimbursed for NMOSD in patients who are 12 years and older, anti-AQP4 positive, have had at least 1 NMOSD relapse in the 12 months before initiation despite an adequate trial of other accessible preventive treatments for NMOSD, or the patient cannot tolerate other preventive treatments for NMOSD. Patients must have an EDSS score of 6.5 points or less |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 PDF file (11 pages) |